INTRODUCTION
Myxomas are rare histologically benign tumors of mesenchymal origin, usually found in the heart. The left ventricle of the heart is the most frequent location, with the thigh and shoulder comprising other frequent soft tissue sites 3) . These tumors are locally aggressive and can be recurrent if en bloc resection is not possible. Intracranial myxomas may have an embolic origin from underlying cardiac myxomas 2) . Primary intracranial myxoma with huge calcification arising from skull base is extremely rare and not well-described in the literature. Small cases of intracranial myxoma have been recorded (Table 1) [6] [7] [8] 11) . In this article, the histological and radiological findings as well as treatment options for a giant primary ossifying intracranial myxoma mimicking a chondrosarcoma will be briefly discussed, together with a review of the relevant literature.
CASE REPORT
A-50-year-old man presented with spontaneous abrupt onset of headache and vomiting, as well as difficulty in standing because of dizziness. This was preceded by a month-long history of progressive hyposmia and feeling generally unwell. Neurological examination revealed only right abducens nerve palsy without signs of other cranial nerve palsies or pyramidal signs. The patient was taking no medication and the rest of his exami-transient frontal lobe syndrome due to a frontal lobe hematoma of the left hemisphere. After three-month the patient returned to work and will be followed-up every 3-6 months by MRI.
DISCUSSION
Myxomas are benign tumors originating in the mesenchyme. They occur equally in males and females and at any age 6) and in diverse organs including heart, skin, bone, and subcutaneous bony component inside right ethmoid sinus (Fig. 3) .
Grossly, the surgical pathology specimens consisted of glistening yellowish soft-to-solid tissue with a large amount of bone (Fig. 4) . Microscopically, they had a myxoid appearance with focal yellowish spots and a fibrous membrane. Immunohistochemically the tumor cells were positive for vimentin and negative for GFAP, S-100, EMA, CD34, and cytokeratin (Fig. 5 ). These findings are consistent with a pathological diagnosis of myxoma. The postoperative course was uneventful except for 6, 9) . Myxomas typically manifest as painless, very slow growing masses in soft tissues or bones, and they may go undetected for several years 1) . If they involve the skull base, as in our case, they frequently develop the signs and symptoms of cranial nerve palsies by the time of diagnosis 12) . Myxomas and chondrogenic tumors usually arise from cartilaginous synchondroses at the skull base. Unlike myxomas, chondrosarcomas are expansile, lobulated, soft tissue masses with endosteal bone resorption. In our case, the tumor was thought to be a chondrosarcoma radiologically. Intraosseous meningiomas and intradiploic epidermoid cysts are rare but do occur, and should be kept in mind in differential diagnosis 7) .
Radiological examination is a decisive tool in the diagnosis of myxoma. CT scans can reveal bone destruction and relatively clear tumor margins. Myxomas may be hypodense to isodense in CT scans, and show variable enhancement patterns 11) , and bone window imaging reveals the degree of bony destruction and the expansile pattern of the mass. More extensive bony growth than bony destruction was observed in our case, but this is a rare finding in mxyoma.
MRI yields an intermediate or low signal intensity on T1-weighted images and a high signal intensity on T2-weighted images, and heterogeneous enhancement is a frequent finding 2, 12) . Radiologically, chondrosarcoma, chordoma, metastatic tumors of the skull, meningioma and epidermoid cysts of the dura and skull base are frequently encountered in differential diagnoses 6, 8, 11) . Histologically, myxomas consist of characteristic hypocellular areas of satellite and spindle cells with a mucoid intercellular substance. The spindle and stellate cells are fibroblasts and myofibroblasts, and absence of nuclear pleomorphism is typical. Therefore, immunohistochemical staining can play a key role in differentiated diagnosis. Characteristically, myxomas stain positively for vimentin and negatively for S-100 protein, neuron-specific enolase, neurofilaments, glial fibrillary acid protein, keratin 1, 5, 8, 10) . The treatment of choice for primary intracranial myxomas is radical surgical removal because they are generally insensitive to radiation therapy 1, 4, 8) . However, a huge primary myxoma of the skull base is still a very challenging tumor, and very difficult to remove totally from the cranial base bone. After gross total removal of such tumors, reconstruction of the cranial base is also a problem. When the bones of the skull base are infiltrated deeply or widely, en bloc total resection is generally impossible. Even if it were feasible, the morbidity and mortality rate would be too high. In our case we opted for subtotal resection of the bony part of the tumor that had infiltrated the ethmoid sinus and it was removed by piecemeal resection, even though that approach was not very satisfying.
Most authors consider myxomas insensitive to radiation therapy 1, 4, 8) . However, Zhang et al. 13) reported one instance in which shrinkage of a myxoma of the skull base was seen at a seven month follow-up after gamma-knife stereoradiotherapy. Total removal of a myxoma originating from a bone of the skull base may be impossible, and radiotherapy may be a salvage treatment, though definitive evidence is not available. Recurrence is common, with 25% of tumors recurring if they cannot be removed radically. Recurrence has been noted as early as 3 months after surgical resection and as late as 10 years after surgical resection 8) . We describe here a rare case of giant primary intracranial ossifying myxoma of the ethmoid sinus, review its histopathology, and emphasize that gross total resection, when possible, is the only definitive treatment.
